Therapeutic targeting of the complement system in age-related macular degeneration

A review

Robyn Troutbeck, Salmaan Al-Qureshi, Robyn H. Guymer

Research output: Contribution to journalReview ArticleResearchpeer-review

49 Citations (Scopus)

Abstract

The last decade has produced pivotal change in our understanding of the molecular mechanisms underlying age-related macular degeneration (AMD), a leading cause of global blindness. In this time, the complement system has featured as a unifying theme for several elements of new evidence: initially, the discovery of complement proteins within drusen and subsequently, the association between AMD and mutations in various complement pathway genes, most notably complement factor H. Increasingly, a wealth of data are pointing towards a role for chronic local inflammation and complement activation in the patho-aetiology of AMD. These findings have paved the way for the exploration of a new paradigm of therapy in AMD management; targeting of specific molecular constituents in the complement pathway thus producing dampening or inhibition of the inflammatory response. Such an approach has the potential to intervene earlier in the disease process and ideally before vision is compromised. In this review we discuss the role of the complement system in AMD, novel therapies in preclinical evaluation and clinical trial, and whether these have a part to play in reducing the burden of disease.

Original languageEnglish
Pages (from-to)18-26
Number of pages9
JournalClinical and Experimental Ophthalmology
Volume40
Issue number1
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Keywords

  • AMD
  • Complement factor H
  • Complement system

Cite this

@article{0925fa7ec3d9492f8a3b96c2d0fbcd3c,
title = "Therapeutic targeting of the complement system in age-related macular degeneration: A review",
abstract = "The last decade has produced pivotal change in our understanding of the molecular mechanisms underlying age-related macular degeneration (AMD), a leading cause of global blindness. In this time, the complement system has featured as a unifying theme for several elements of new evidence: initially, the discovery of complement proteins within drusen and subsequently, the association between AMD and mutations in various complement pathway genes, most notably complement factor H. Increasingly, a wealth of data are pointing towards a role for chronic local inflammation and complement activation in the patho-aetiology of AMD. These findings have paved the way for the exploration of a new paradigm of therapy in AMD management; targeting of specific molecular constituents in the complement pathway thus producing dampening or inhibition of the inflammatory response. Such an approach has the potential to intervene earlier in the disease process and ideally before vision is compromised. In this review we discuss the role of the complement system in AMD, novel therapies in preclinical evaluation and clinical trial, and whether these have a part to play in reducing the burden of disease.",
keywords = "AMD, Complement factor H, Complement system",
author = "Robyn Troutbeck and Salmaan Al-Qureshi and Guymer, {Robyn H.}",
year = "2012",
month = "2",
doi = "10.1111/j.1442-9071.2011.02581.x",
language = "English",
volume = "40",
pages = "18--26",
journal = "Clinical and Experimental Ophthalmology",
issn = "1442-6404",
publisher = "Wiley-Blackwell",
number = "1",

}

Therapeutic targeting of the complement system in age-related macular degeneration : A review. / Troutbeck, Robyn; Al-Qureshi, Salmaan; Guymer, Robyn H.

In: Clinical and Experimental Ophthalmology, Vol. 40, No. 1, 02.2012, p. 18-26.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Therapeutic targeting of the complement system in age-related macular degeneration

T2 - A review

AU - Troutbeck, Robyn

AU - Al-Qureshi, Salmaan

AU - Guymer, Robyn H.

PY - 2012/2

Y1 - 2012/2

N2 - The last decade has produced pivotal change in our understanding of the molecular mechanisms underlying age-related macular degeneration (AMD), a leading cause of global blindness. In this time, the complement system has featured as a unifying theme for several elements of new evidence: initially, the discovery of complement proteins within drusen and subsequently, the association between AMD and mutations in various complement pathway genes, most notably complement factor H. Increasingly, a wealth of data are pointing towards a role for chronic local inflammation and complement activation in the patho-aetiology of AMD. These findings have paved the way for the exploration of a new paradigm of therapy in AMD management; targeting of specific molecular constituents in the complement pathway thus producing dampening or inhibition of the inflammatory response. Such an approach has the potential to intervene earlier in the disease process and ideally before vision is compromised. In this review we discuss the role of the complement system in AMD, novel therapies in preclinical evaluation and clinical trial, and whether these have a part to play in reducing the burden of disease.

AB - The last decade has produced pivotal change in our understanding of the molecular mechanisms underlying age-related macular degeneration (AMD), a leading cause of global blindness. In this time, the complement system has featured as a unifying theme for several elements of new evidence: initially, the discovery of complement proteins within drusen and subsequently, the association between AMD and mutations in various complement pathway genes, most notably complement factor H. Increasingly, a wealth of data are pointing towards a role for chronic local inflammation and complement activation in the patho-aetiology of AMD. These findings have paved the way for the exploration of a new paradigm of therapy in AMD management; targeting of specific molecular constituents in the complement pathway thus producing dampening or inhibition of the inflammatory response. Such an approach has the potential to intervene earlier in the disease process and ideally before vision is compromised. In this review we discuss the role of the complement system in AMD, novel therapies in preclinical evaluation and clinical trial, and whether these have a part to play in reducing the burden of disease.

KW - AMD

KW - Complement factor H

KW - Complement system

UR - http://www.scopus.com/inward/record.url?scp=84856633285&partnerID=8YFLogxK

U2 - 10.1111/j.1442-9071.2011.02581.x

DO - 10.1111/j.1442-9071.2011.02581.x

M3 - Review Article

VL - 40

SP - 18

EP - 26

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

SN - 1442-6404

IS - 1

ER -